Wackersdorf, April 2022: Pharma and medical technology specialist Gerresheimer has been awarded platinum status by its customer Chiesi. Classification as an especially high-quality supplier is based on a rating process carefully examining sustainability, economy, quality, innovation, and service level.
Gerresheimer secured a top position in its customer Chiesi’s evaluation of the supply chain. Of the participating suppliers, only 9 percent exceeded the minimum score required for platinum status. In the individual rating in the categories of sustainability, economy, quality, innovation, and service level, Gerresheimer performed above average, often achieving the highest evaluation of all participants, as was the case with product quality (100/100) and service level (88/100), for example.
Chiesi placed a special focus on sustainability. The goal is not only to generate more added value for shareholders but to balance the benefits for humanity, the planet, and financial targets. In the Chiesi Code of Interdependence, the Group pledges to only work with partners in its value chain that share its commitment to sustainability, meet the same high standards in terms of environmental compatibility, social performance, and transparency, and do fair, responsible business. In the category of sustainability, in particular, Gerresheimer scored with its ratings for its business ethics (100/100) and its management system (93/100). As a platinum partner, Gerresheimer now plays a key role in developing a sustainable value chain. Among other things, Chiesi has set itself the goal of achieving CO2 neutrality by 2035.
Headquartered in Parma, Italy, the Chiesi Group is an international research-oriented pharmaceutical and healthcare company with more than 85 years of experience that is active in 30 countries with over 6,000 employees. To accomplish their task of improving quality of life while acting responsibly in terms of society and the environment, the Group researches develops, and markets innovative therapy solutions in the three main areas of Air (products and services to support the breathing of newborns all the way to adults), Rare (treatment of patients with rare and very rare diseases) and Care (products and services to support special treatments and for consumer self-care). In 2019, Chiesi became the largest B Corp-certified pharmaceutical company in the world. The global B Corp movement fosters companies as a force for good.
Gerresheimer is the global partner for pharmacy, biotechnology, health, and cosmetics, with a very broad product spectrum for drug and cosmetic packaging, as well as drug delivery devices. The company is an innovative provider of solutions, extending from the concept to the delivery of the final product. Gerresheimer achieves its ambitious goals through a high degree of innovative strength, industrial competence, as well as concentration on quality and customer focus. Gerresheimer trusts in an extensive international network with many innovation and production centers in Europe, America, and Asia when developing innovative and sustainable solutions. With around 10,000 employees, Gerresheimer produces close to the customer worldwide and generates an annual turnover of more than Euro 1.4 billion. With its products and solutions, Gerresheimer plays a central role for the health and well-being of people.